ReviewMolecular diagnosis & therapy2008
Early detection of colon cancer: new tests on the horizon.
Review in Molecular diagnosis & therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Serum tests for colorectal cancer screening.Molecular diagnosis & therapy · 2011Pooled it
- Review
- Volatile Organic Compounds in Biological Matrices as a Sensitive Weapon in Cancer Diagnosis.Pharmaceuticals (Basel, Switzerland) · 2025Review
- S100A11 as an immune-related exosomal driver of colorectal cancer progression: a novel diagnostic biomarker.Frontiers in oncology · 2025Article
- Potential of pre-diagnostic metabolomics for colorectal cancer risk assessment or early detection.NPJ precision oncology · 2024Article
- Evaluation of the Plasma Expression Levels of miR-21 and miR-145 as Potential Non-Invasive Biomarkers for Early Detection of Colorectal Cancer.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- The Association between Colorectal Cancer and Colonoscopic Conditions in Saudi Patients: A 10-Year Cross-Sectional-Retrospective Study.Ethiopian journal of health sciences · 2022Article
- A comparative examination of colorectal cancer burden in European Union, 1990-2019: Estimates from Global Burden of Disease 2019 Study.International journal of clinical oncology · 2022Article
- Regulation of signal transduction pathways in colorectal cancer: implications for therapeutic resistance.PeerJ · 2021Article
- Antitumorigenic Effects of Inhibiting Ephrin Receptor Kinase Signaling by GLPG1790 against Colorectal Cancer Cell LinesJournal of oncology · 2020Article
- Diagnostic Value of Combining miRNAs, CEA Measurement and the FOBT in Colorectal Cancer Screening.Cancer management and research · 2020Article
- Alterations in folate-dependent one-carbon metabolism as colon cell transition from normal to cancerous.The Journal of nutritional biochemistry · 2019Article
- Exploratory metabolomic study to identify blood-based biomarkers as a potential screen for colorectal cancer.Molecular omics · 2019Article
- Review
- Quantitative mass spectrometry analysis reveals a panel of nine proteins as diagnostic markers for colon adenocarcinomas.Oncotarget · 2018Article
- Colorectal cancer screening in countries of European Council outside of the EU-28.World journal of gastroenterology · 2016Review
- Simultaneous Analysis of SEPT9 Promoter Methylation Status, Micronuclei Frequency, and Folate-Related Gene Polymorphisms: The Potential for a Novel Blood-Based Colorectal Cancer Biomarker.International journal of molecular sciences · 2015Article
- Introducing biomarker panel in esophageal, gastric, and colon cancers; a proteomic approach.Gastroenterology and hepatology from bed to bench · 2015Review
- Current Challenges in Volatile Organic Compounds Analysis as Potential Biomarkers of Cancer.Journal of biomarkers · 2015Review
- Competition in Colon Cancer Screening? What Is the Role of Colonoscopy?Viszeralmedizin · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This year, the American Cancer Society reported that the rate of decline in both the incidence and mortality of colorectal cancer has increased over the last two decades. This success is felt to be attributable to the early detection and treatment of colonic adenomas and early-stage colorectal cancers. However, the current recommended 'menu of options' for screening is limited by poor patient acceptance, low sensitivity, and both high cost and poor accessibility for application to a large general screening population (colonoscopy). Computerized tomography and magnetic resonance colonography offer an alternative method for the identification of polyps and early lesions in certain patients, but have cost, access, and acceptance limitations that are similar to those of colonoscopy; thus, they present similar barriers to their use in broad population screening. These limitations provide a strong rationale for the development of early colorectal cancer detection biomarkers that are simple to use and are cost effective. A successful biomarker or biomarker panel, coupled with the colonoscopic follow-up of only those patients with positive results, would reduce the burden and morbidity associated with the screening of colonoscopy. This would most likely result in enhanced adherence to colorectal screening, as well as a dramatic reduction in the incidence and mortality rates of colorectal cancer. In this paper, we review recent advances in the discovery of potential colorectal cancer biomarkers. Their applicability to clinical population screening will require large prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.